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Abstract
Survival analysis with high dimensional data deals with the prediction of patient
survival based on their gene expression data and clinical data. A crucial task for
the accuracy of survival analysis in this context is to select the features highly
correlated with the patient’s survival time. Since the information about class labels
is hidden, existing feature selection methods in machine learning are not applicable.
In contrast to classical statistical methods which address this issue with the Cox
score, we propose to tackle this problem by discretizing the survival time of patients
into a suitable number of subgroups via silhouettes clustering validity. To cope with
patient’s censoring, we use “k-nearest neighbor” based on clinical parameters that
are truly associated with survival time. These are selected using penalized logistic
regression and the penalized proportional hazards model with the EM algorithm.
They are then used to estimate censored survival time. Next, the estimated class
label is combined with feature selection to identify a list of genes that are correlated
with the survival time and classifiers are applied to this subset of genes to determine
which subtype is present in a future patient. By doing so, we expect that the identified
subgroups are not only biologically meaningful but also differ in terms of survival.
The effectiveness and efficiency of the proposed method are demonstrated through
comparisons with classical statistical methods on real-world datasets and simulation
datasets.
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Chapter 1
Introduction
1.1 Motivation
Cancer, the leading cause of death in Canada, accounted for 30% of all deaths in
2015 [12]. When a patient is diagnosed with cancer, a number of clinical parameters
are used to assess the patient’s survival profile. While a certain form of cancer, lung
cancer for instance, is often thought of as a single disease, growing evidence suggests
that there are multiple subtypes of a specific cancer disease that occur with clinically
significant differences in survival [57]. One possible explanation is that two seemingly
alike tumors are actually completely different diseases at the molecular profile of the
tumor [33, 16, 58]. With the aim to ultimately improve the clinical management of
cancer disease, researchers have sought to specify the subtypes of newly diagnosed
patients, especially when those subtypes are associated with patient’s survival time,
or elicit different prognoses and responses to certain therapies.
After collecting the survival information of a group of cancer patients with the
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same clinical diagnosis, the survival prognosis can be predicted by studying the
patients’ survival profiles. Figure 1.1 illustrates the survival information obtained
from the application of the method proposed in this thesis to one dataset, in which
all patients have the same clinical lung cancer diagnosis [5]. As can be seen in Figure
1.1a, patients with this type of cancer are at a high risk with the median survival time
around 30 months, that is, only 50% of patients are expected to survive beyond 30
months. This type of fatal cancer must be treated aggressively, although aggressive
treatments have potentially serious side effects. However, Figure 1.1b indicates that
there exists another subtype of this cancer, which is distinguished by a difference at
the molecular level of the tumor.
Figure 1.1: Kaplen-Meier survival plots for (a) one identified subgroup and (b) both
stratified subgroups of the lung cancer dataset.
Compared to patients with the previous subtype, subjects with this alternative
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subtype have a considerably improved long-term survival rates, with a median
survival time of around 55 months. Patients with this less aggressive cancer can
be treated with milder medications and still have excellent outcomes. In addition,
patients diagnosed with the same type of cancer have different responses to different
treatments; they may also respond differently to the same treatment [79, 56].
Therefore, a specific type of cancer is not a single disease, and there is an urgent
need to identify the subtypes of cancers and diagnose patients accordingly.
Cancer subtypes provide clues into patient disparities with respect to survival
time, and can help in designing more targeted treatment strategies and more effective
therapies. In recent years, a number of methods have been proposed for diagnosing
patients with a particular tumor subtype when the subtypes are already known [80].
When neither the subtypes nor the number of subtypes are known in advance, the
issue of identifying such subtypes becomes much more complicated. The scientific
community has been using clinical information to develop techniques to identify
cancer subtypes in the diagnosis of future patients [47, 22, 11, 6]. However, this
problem still remains a largely open research question and further research is required
[76].
To date, all efforts towards solving this problem fall into a class of statistical
procedures [4, 3, 5], and there is rarely study on identifying subtypes associated with
survival using the techniques proposed by computer scientists in the machine learning
community. Statistical procedures have achieved varying degrees of success. However,
their effectiveness diminishes in coping with high-dimensional data as selecting
relevant features irrespective of redundancy jeopardizes generalization capability
[58]. Moreover, selecting relevant features by iteratively fitting a univariate Cox
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proportional hazards model is time-consuming, especially in high-dimensional setting.
The aforementioned research sparks our interest in exploring the feasibility of
applying the machine learning approach, in the context of survival data, to identify
subtypes of cancer and to use this knowledge to diagnose future patients. Compared
with the methods from statistical perspective, feature selection in machine learning
possesses not only high relevancy, but also low redundancy with respect to the
phenotype of interest. Furthermore, most of them are model free, which allows for
wide applicability and easy implementation. This thesis describes a new approach
that utilizes both gene expression data and clinical data to conduct feature selection
and survival prediction from the machine learning perspective. The main goal is to
open a range of possibilities for future work on designing a more powerful tool for
diagnosing and treating cancer from a different class of techniques.
1.2 Research Questions
The main objective of this research is to address issues surrounding the prediction of
patient survival from high-dimensional survival data. Since this research lies beyond
the traditional research paradigm that falls into the class of statistical procedures,
it leads to some fundamental research questions related to the value of the proposed
methodology:
How can machine learning approaches be applied to predict patient
survival from high-dimensional survival data?
The value of diagnosing and prognosing the subtypes of different cancers is well-
established [69, 8, 23], especially when neither the subtypes nor the number of
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subtypes are known [47, 25, 81]. There is an extensive body of literature on survival
analysis with high-dimensional data for selecting significant features, identifying
cancer subtypes, and predicting future observations [43, 22, 11]. To the best of my
knowledge, all reported methods fall into the class of statistical category.
The foundation of these methods in selecting significant features but also
evaluating future patients is the Cox score derived from the well-known and widely
used Cox proportional hazards model [74]. The Cox score quantifies how well a
feature predicts survival by fitting a univariate Cox proportional hazards model for
each individual feature, regardless of the availability of class label. Using the Cox score
as a basis, statisticians employ a variety of methods to identify significant features
that are likely to be associated with survival and all these methods exclusively involve
computing Cox score or the variants of Cox score[76, 43]. Although feature selection in
machine learning is model-free and highly efficient for high-dimensional data, there is
a limited number of related studies on high-dimensional survival data. One obstacle
is that feature selection in machine learning necessitates the dependence on class
label. Therefore, finding a way to determine the hidden class label is necessary. This
research question will be answered in Chapter 3.
What is the feasibility of using the machine learning approach for high-
dimensional survival data?
In this study, we developed procedures to select significant features and to
stratify newly diagnosed patients into identified subtypes from the machine learning
perspective. As such, this work can be classified as an empirical study in survival
analysis for high-dimensional data. In high-dimensional survival data studies, the
central aim is to develop tools to diagnose different subtypes of cancer, including
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subtypes that are already known to exist and those that are unknown, in order to
improve the clinical management of cancer disease [80, 8, 1]. Therefore, one of the
research questions of this thesis is to explore the feasibility of the proposed approach
on the measures of efficiency and effectiveness. In this research, “efficiency” refers to
the time requires for feature selection methods to identify a list of significant genes,
whereas “effectiveness” gauges the significance of the selected genes and the quality
of the survival prediction of future patients. This research question will be addressed
by an empirical study described in Chapter 4.
1.3 Approach
The task of identifying cancer subtypes involves the discovery or identification of
survival classes or meaningful groups of objects that hold vital implications for
survival time. Technically speaking, the objectives are to identify a set of latent
class memberships that are associated with the phenotype of interest. Within the
identification process, the initial step of many existing methods is to subset the feature
space into a relevant subset of features. In this research, a diagnostic procedure that
makes use of both the subsetted gene expression data and the clinical data of previous
patients was employed to predict survival of future patients.
The first aspect we considered was selecting an informative subset of features
from an existing feature space. However, unlike statistical variable selection method,
since the information about class label is hidden, the existing feature selection in
machine learning is not applicable. We tackled this problem by discretizing the
survival time of patients into a suitable number of subgroups via silhouettes clustering
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validity [66]. The second step was to employ machine learning classifiers to diagnose
future patients [61]. Although several different subtypes of a certain form of cancer
might exist, if the prognosis for all patients is the same regardless of patient survival,
the subgroups predicted in future patients may not differ in terms of survival. We
therefore used class labels relied on clinical data along with feature selection, to
identify a list of genes that were significantly associated with survival. Classifiers were
applied to this subset of genes to predict the subtype for a future group of patients.
Finally, empirical evaluations were conducted on both publicly available datasets and
simulation datasets in order to explore the efficiency and effectiveness of the specific
design choices in comparison to current statistical approaches. Overall, a practical
research methodology was employed to predict the survival of future patients. This
methodology employs techniques mainly from the machine learning perspective and
is in contrast to approaches that fall into the class of statistical category.
1.4 Organization of the Thesis
The remainder of this thesis is organized as follows:
In Chapter 2, the basic concepts of survival analysis will be presented. This
includes descriptions of existing methodologies and related techniques used in this
thesis, as well as an overview of statistical methods for the analysis of high-
dimensional survival data in the literature.
In Chapter 3, the proposed approach for analyzing high-dimensional survival data
from the machine learning perspective is described. Selecting significant features and
predicting identified subtypes in the future patients with the help of machine learning
7
approach are discussed, respectively.
In Chapter 4, the results of a real-world data analysis and a simulation study
using our approach are discussed in detail.
The thesis concludes in Chapter 5 with a summary of the study’s contributions,
and suggestions for future research.
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Chapter 2
Survival Analysis with
High-Dimensional Data
This chapter provides an introduction to some concepts essential to survival analysis,
including censored data, survival functions, and models used to estimate survival
processes. A review of statistical methods for the analysis of high-dimensional survival
data and related techniques follows.
2.1 Survival Analysis
2.1.1 Survival Data
The main outcome addressed in survival analysis is the time at which an event of
interest occurs. Events of interest can refer to any experience had by an individual:
their response to treatment, their recurrence of or recovery from a disease, or any
designated experience of interest that occurs in an individual. The span of the event
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of interest, starting from the beginning of the follow-up of an individual in the study
until an event occurs, is called the survival time. Survival time can be considered as
either a negative or positive experience. For instance, the duration spent in remission
following surgical removal of a primary tumor is a negative event, while returning
home after a stay in the hospital due to an infection following cardiac surgery is
regarded as positive.
The purpose of analyzing survival data is to determine the proportion of cured
patients, define the possible effects of covariates, and predict future survival [43]. If
the event of interest occurs in all individuals of the study cohort, usually referred
to as uncured or susceptible, survival analysis does not give advantage over other
methods of analysis. The benefits of survival analysis occur when only a portion of
individuals have experienced the event by the end of the study period. This results in
access to only a subset of survival information from the study cohort, a phenomenon
called censoring.
Figure 2.1 illustrates the concepts of censoring. Suppose we are interested in the
time spent in remission by a group of cancer patients, following surgical removal of
a primary tumor. In this example, the event of interest is relapse from remission,
and the survival time is from the beginning of the patient’s follow-up until relapse.
Censoring occurs in this example because there are insufficient data to determine the
exact duration of remission. For example, Patients 2, 3, 5 and 6 entered the study
at different times and their survival times vary; however, their survival times are not
censored simply because they all relapsed from remission before the end of the study.
As long as the participant experiences the event of interest before the end of the study,
he/she belongs to the category not censored. On the other hand, Patient 1 withdrew
10
Figure 2.1: Dashed vertical line is the end of study period, N = relapse from remission,
 = censored.
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from the study due to an event that was not of interest, making further follow-up
impossible; Patient 4 did not experience the relevant outcome by the end of the study;
and Patient 7 was lost to follow-up during the study period. Therefore, their exact
survival times in the study period are unknown, and as such they are all censored,
the censored survival times for Patient 1, 4 and 7 are 3 years, at least 6 years, and
2 years, respectively. These three examples serve to illustrate how censoring usually
occurs.
There are three types of censored event: right, left and interval censored. Right
censored events are those that continue beyond the end of the follow-up period. This
case applies to Patient 4, who entered the study at the beginning and was monitored
until the sixth year (i.e., the end of the study) without the event occurring. Patient
4’s survival time is at least six years. Suppose, however, that Patient 4 entered the
study sometime after surgery and experienced relapse from remission before the end
of the study. This is a left censored event, which means that the actual survival
time is less than or equal to the observed time of recurrence. Alternatively, assume
several years after the study ends we are interested in the study again. If Patient 4
experienced the event of interest within the time interval or was lost to the follow-up,
Patient 4 is then considered to be interval censored. This means the true time is
within a known time interval [38]. Although left and interval censoring do exist, most
survival data is right censored. We refer to only right censored data in the discussion
to follow. In addition, independent censoring, random censoring, and non-informative
censoring are three assumptions taken into account in the analysis of survival data,
that is, the event and censoring time for each patient are independent and the reason
for censoring is not specified [43].
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2.1.2 Basic Tools for Survival Analysis and Related
Techniques
Throughout this thesis, we often use the survival analysis terms Kaplan-Meier, Cox
proportional hazards model, Mixture cure model and so forth interchangeably. We
now turn our attention to describing these basic tools for survival analysis. Kalbfleish
and Prentice give an excellent review on the subject and their many applications [39].
Related techniques used in the current work are also presented in the section.
2.1.2.1 Terminology and Notation
Three different variables T, t and δ are widely used in survival data. Each individual’s
survival time is a random variable commonly defined as T, while t denotes any specific
value of the random variable T, that is, any value of the event of interest. Since T
denotes time, its value is always greater than or equal to zero. This is the case for t
as well. The binary random variable δ is assigned 1 or 0 to indicate the absence or
presence of censorship, respectively. When a person has not experienced the event by
the end of the study, has been lost to follow-up or withdraws from the study, their
survival time is censored, and δ equals 0. In the absence of censorship, the patient
experiences the event before the end of the study, and δ equals 1 [43].
Survival data is usually considered and modeled in terms of two quantitative
terms: the survivor function and the hazard function, denoted by S(t) and h(t),
respectively [64]. The former gives the probability that an individual will survive
from the start time to a specific future time, t. The survivor function is essential
to survival analysis because obtaining survival probabilities for different values of t
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provides a crucial summary of information from the time patients enter the study to
the event of interest. Depending on these values, we can gain a general view of the
study cohort’s survival experience. Theoretically, the value of S(t) decreases from
1 to 0 when t increases from 0 to infinity. That is becasue at the beginning of the
follow-up (i.e., t = 0), no one has experienced the event yet, so S(0) = 1. When t
approaches infinity, that is, when the study period increases without limitation, every
study participant would theoretically experience the event of interest, so S(∞) = 0.
When dealing with actual survival data, however, the study period is finite in length.
Furthermore, an individual may withdraw from the study or may be lost to follow-up
during the study period, so not everyone will necessarily experience the event. In
other words, the value of S(t) may be greater than zero rather than decreasing all the
way to zero at the end of the study. Figure 2.2 shows a typical graph of a survival
function.
Figure 2.2: An illustration of the survival function S(t)
14
In contrast to the survival function, the hazard function investigates the incident
event rate, which is the instantaneous potential per unit time which happens an event
under observation at a specific time, t. The value of the hazard function can range
from 0 to infinity, and can either be increasing, decreasing or remain constant (i.e.,
stability is maintained throughout the study). These three types of survival functions
are depicted in Figure 2.3, respectively, in lines a, b and c. Line a might be expected
for patients not responding to treatment and patients recovering from surgery can be
represented by line b. Line c occurs when a person continues to be healthy throughout
the study period [59].
Figure 2.3: Graphs depicting h(t) as (a) an increase function, (b) a decrease function,
and (c) a constant function.
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There is a clearly defined relationship between the survival functions and hazard
function. Knowing the formula for S(t), the corresponding formula for h(t) can be
determined, and vice versa. The general formula is expressed as follows:
S (t) = exp
[
−
t
∫
0
h (u) du
]
(2.1)
h (t) = −
[
dS (t) /dt
S (t)
]
(2.2)
In survival analysis, the Kaplan-Meier (KM) model is frequently used to plot
and interpret survival data. After we generate KM curves, the log-rank test can be
conducted to help us assess the information revealed by the KM curves and test their
equivalency. Other popular test methods include the Cox proportional hazards model
and mixture cure model, to name a few. We will discuss the background and use of
each of these methods in the following sections.
2.1.2.2 Kaplan-Meier Model
The Kaplan-Meier (KM) model is a nonparametric test for estimating the survival
probability from survival data [40, 59]. It is typically used to estimate the proportion
of a cohort, both censored and uncensored, who survive from the start time to a
specified future time t. Equation 2.3 is the general formula for the Kaplan-Meier
model:
S (tj) = S (tj−1) × Pr(T > tf | T ≥ tf ) = S (tj−1)
(
1− di
nj
)
(2.3)
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Recall that S(t) gives the probability that a patient survives from the time of origin
to a specific time, t. Suppose that N individuals have the following survival times in
non-descending order: t1 ≤ t2 ≤ t3 ≤ ... ≤ tn−1 ≤ tn. Equation 3 gives the probability
of surviving over the interval tj−1 to tj. A formal way to express the formula is that
S(tj), the survival probability of being alive at tj, is the multiplication of S(tj−1),
those who survive at the last previous time, and (1− di
nj
), those who survive over the
interval between them, where nj is the number of individuals alive just before tj, and
dj is the number of events at tj. A decrease in the number nj during the interval
may result from either the subject experiencing the event of interest or the subject
being censored within the interval period. Censored individuals need to be taken into
account in the total number of individuals available at tj.
Figure 2.4 shows as an example of the KM step function plot for a set of survival
data that we generated from simulating the distribution of the lung cancer dataset
[5]. This generated dataset includes each patient’s curing and censoring status as
well as their corresponding failure time. By selecting the appropriate parameter
values, the data was generated with a higher cure rate to better illustrate survival
data with a cured proportion. A univariate was generated with binary values 1 and
0 to represent two different groups. This is relevant, for instance, when comparing
treatment versus placebo in a clinical trial. The details describing data generation in
this thesis, including simulation data used for testing the later proposed method, will
be covered in section 4.2.1.
As we can see from Figure 2.4, the estimated relapse-free survival curve from
the “Feature1 Equals 1” group is always above or at least at the same level as the
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“Feature1 Equals 0” group. This indicates that the survival probability of patients
from the former group is higher than that of the latter group, that is, the former group
experiences more effective treatment. Figure 2.4 also indicates that both curves level
off at a value substantially greater than 0 after a period of follow-up, which means
that some patients will not experience the recurrence of their disease after undergoing
treatment. Therefore, an innegligible portion of the population in both groups may
never experience the event of interest.
Figure 2.4: KM plot for survival data with cured patients
Alternatively, if we generated data with patients who experience the event of
interest only, the KM plot would appear as shown in Figure 2.5. Although the
estimated relapse-free survival curve from the “Feature1 Equals 1” group is always
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at the same level or above the “Feature1 Equals 0” group, both curves level off at 0,
which means both groups experience recurrence of their disease in the end.
Figure 2.5: KM plot for survival data without cured patients
The KM plot depicted in Figure 2.4 and 2.5 represent two common scenarios.
The Kaplan-Meier method graphs survival curves for different patient groups, and
the width of the gap between groups suggests the degree of visual difference or
inequivalence. To quantify the difference, the log-rank test can be applied to
statistically calculate the overall population survival difference [2].
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2.1.2.3 The Cox Proportional Hazards Model
A number of statistical methods have been proposed for modeling survival analysis
data. Among them, the Cox proportional hazard model and mixture cure model are
widely used. In this section, we will describe the Cox proportional hazards model,
abbreviated to Cox model or PH model, and demonstrate its application [20]. The
mixture cure model is discussed in next section. The Cox PH model is usually written
in the form given in Equation 2.4:
h (t, x) = h0 (t)× e
p∑
i=1
βixi
(2.4)
where x = (x1, x2, . . . , xp)
The formula describes the instantaneous event rate at a given time t, where t is
determined by the hazard function and specification of a set of covariates denoted
by X. The term h0 (t) is called the baseline hazard function and occurs when all
the xi values are equal to zero. The exponential part of the formula only contains
the time-independent variable X, which does not change in value as the time varies.
One reasonable way to estimate the regression coefficients β is to apply the partial
likelihood estimation [17]. The function can be written as follows:
L (β) =
∏
r ∈ D
exp
(
βTXr
)∑
i ∈ Rr exp (β
TX i)
(2.5)
In Equation 2.5, D is the set of indices of the failures, Rr is the set of indices of
the individuals at risk at time tr−0 including the censoring individuals, and r is the
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index of the failure at time tr. In order to estimate β, we first fit the Cox PH model
then maximize the partial likelihood function. It is worth noting that this approach
cannot be used directly to estimate β with respect to the small n (the number of
observations) large p (the number of covariates) problem, that is, when the number
of covariates exceeds the number of observations [4, 13]. This setting is referred to as
“high-dimensional”.
2.1.2.4 The Mixture Cure Model
The unstated assumption behind the Cox Proportional Hazard model is that all
patients will eventually experience the event of interest, given a sufficient follow-
up time. Remarkable advances in medicine, however, have increasingly made lethal
diseases curable. Also, long-term survivors are statistically regarded as cured when
an innegligible proportion of patients will never experience disease recurrence (i.e., an
estimated Kaplan-Meier survival curve will reach a plateau after a certain time) [46].
In the case where a large percentage of the cohort does not experience recurrence,
standard survival models fail to provide a good understanding of the survival process
[30].
In contrast to standard survival models, the mixture cure model, first introduced
by W. Boag [9], accounts for the possibility that some patients will be free
of recurrence. This model is often selected when standard survival models are
inadequate, and it provides insight into factors that affect susceptibility and
recurrence. The mixture cure model can be expressed as follows:
S (t|X, Z) = Pr (T > t |x, z) = P (z) + (1− P (z)) S (t|x) (2.6)
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where P (z) models the proportion of non-susceptible patients, conditional upon z
(i.e., the probability of being cured) and is usually referred as the “incidence”; and
S (t|x) denotes the survival probability of the uncured patients given x and is referred
to as “latency”. Note that x and z are the observed values of two covariate vectors that
affect the survival function. Although we use different covariate notations, identical
covariates are allowed for these two components.
The standard formula of the mixture cure model in Equation 2.6 can be regarded
as the combination of the cure-rate function and the survival function. The left side
of the equation (the incidence segment) models the probability of the patients being
cured and the remainder (the latency segment) is the survival distribution of uncured
patients. These two segments help us differentiate the study cohort as individuals
who will remain free of disease in the long term and those who are out of remission
within the study period.
Various models for the incidence segment have been proposed, such as the logistic
regression model, log-log model and probit model. Similar to the proportional hazard
model, the latency segment can be derived from the Weibull distribution and the
Exponential distribution, among others [43]. The Weibull model in particular has
been found to provide a good description of many types of lifetime data and is widely
used in biomedical applications [48]. In addition, the logit link function is typically
used to model the effect of z. The logistic regression model and Weibull model are
formulated as follows, where λi = e
βx:
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P (Z) =
exp
(
p∑
i=1
γizi
)
1 + exp
(
p∑
i=1
γizi
) (2.7)
S (ti|xi) = exp
(
−λitβi
)
(2.8)
2.1.2.5 The Lasso Method for Variable Selection
When fitting models, the “best” subset of variables has to be determined. There are
many different variable selection methods and these fall into two broad categories: (1)
the discrete method, for example the stepwise selection [15]; and (2) the continuous
method, such as the shrinkage-based method [82]. This research employs the
shrinkage-based method that uses L1 penalty, that is, the Least Absolute Shrinkage
and Selection Operator (Lasso) [73], to select important factors for the mixture cure
model considering its stable and efficient merits.
Consider the typical survival data setup: we have data (yi, xi, δi), i = 1, ... , n,
where xi represents the vector of predictors and yi is the observed survival time. The
event is complete if δi = 1 and is right censored if δi = 0. Take Equation 2.5 as an
example and denote the log partial likelihood by l (β) = logL (β). Lasso is used to
solve the original problem by adding a constraint as the penalty,
argmin l (β) , subject to
∑
|βi| ≤ t (2.9)
or equivalently to solve the problem,
argmin
{
l (β) + nλ
∑
|βi|
}
(2.10)
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where t, or alternatively λ, is a tuning parameter. Note if
∑ |βi| > t, the solutions
to Equation 2.5 are the usual partial likelihood estimates. If
∑ |βi| ≤ t, however,
some coefficients shrink to 0. The strategy for solving Equation 2.9 is to express the
usual Newton-Raphson update as an iterative reweighted estimation step, and then
replace the weighted estimation step by a constrained weighted estimation procedure
[36]. The procedure is outlined as follows:
1. Start with E = {j0} where δj0 = sign
(
βˆ0
)
, and βˆ0 is the ordinary estimate.
2. Find βˆ to minimize the l (β) subject to GEδ ≤ t · 1.
3. If
∑ |βi| ≤ t, then stop; otherwise proceed to step 4.
4. Add δj = sign
(
βˆ
)
to GE, that is, let GE =
 δTj
δTi
, and return to step 2.
Note that if an unconstrained minimization was instead used in step 2, this
procedure would be identical to the usual Newton-Raphson algorithm for maximizing
the partial likelihood [17].
In terms of the tuning parameter t, data-driven methods, such as generalized cross
validation (GCV) can be used to determine the best t value [29]. The GCV statistic
is
GCV (t) =
1
N
− lt
N
[
1− p (t)/N
]2 (2.11)
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where p (t) is the effective parameters and lt is the log-partial likelihood for the
constrained fit with constraint t. Intuitively, the GCV criterion inflates the negative
log partial likelihood by a factor that involves p (t). As Chapter 3 will reveal, Lasso
is used as the penalty function to generate the new penalized likelihood function as
the clinical parameter selection.
2.1.2.6 Discretizing Continuous Features
After the discussion of basic survival analysis tools, a fundamental technique,
discretization, of this work is covered in this section. Discretization is usually
performed to search for the width, or the boundaries of the arity of intervals given
the range of values of a continuous attribute. In doing so, a set of landmarks that
partition the range of values are identified. A typical discretization process is shown
in Figure 2.6. It usually starts with optionally sorting data in ascending or descending
order with respect to the continuous values of the variable to be discretized. After
the sorting step, landmarks are chosen among the whole dataset to either divide
the range into intervals or merge adjacent intervals according to some evaluation
function equipped with a stopping criterion; the evaluation function measures class
coherence, and the iteration process is terminated when the number of inconsistencies
or the misfit measure is deemed to be below a given tolerance. The stopping criterion
involves a trade-off: lesser artity gives a better understanding but lower accuracy,
and more arity is accompanied by a poorer understanding but higher accuracy.
Researchers in the machine learning community have introduced numerous evaluation
functions, and an overview of discretization algorithms can be found in [26].
Previous work on continuous feature discretization can be categorized into
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Figure 2.6: The typical discretization process
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unsupervised discretization methods, such as equal width interval binning (EW), or
supervised discretization methods such as ChiSplit, which maximizes the chi-square
criterion applied to the two sub-intervals adjacent to the splitting point [45]. The
difference between the two types of methods is the presence of a class label in the
discretization process. Alternatively, discretization methods, namely global or local,
can be identified by different axes. Binning, for example, is a global discretization
method that produces a mesh over the entire continuous instance space. Local
discretization methods perform the partition at localized regions of the instance, as
exemplified by C4.5 [49]. Other dimensions of discretization methods are direct or
incremental, static or dynamic, and top-down or bottom up [35]. Table 2.1 provides
a two-dimensional summary of some representative discretization methods classified
by the global/local and supervised/unsupervised axes.
Table 2.1: Summary of discretization methods
We now describe in detail two unsupervised discretization methods (equal width
interval binning and k-means clustering), and two supervised discretization methods
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(Holte’s 1R discretizer and recursive minimal Entropy Partition). The simplest
discretization method, equal width interval binning (EW), determines the minimum
and maximum values of the continuous attribute, and then divides the range of
observed values into k bins of equal width discrete intervals, where k is the user-
defined parameter. Equal width interval binning has been widely applied as a means
of producing nominal values from continuous features. The process is irrespective
of instance class information, and each feature is partitioned into a sub-range
independent of the other attributes. Thus, EW is an unsupervised as well as a
global discretization method. The obvious weakness of the EW method is that it is
vulnerable to the distribution of attributes with heavy-tailed or outliers [14].
The majority of systems using unsupervised methods carry out global discretization
with the exception of another common discretization technique: k-means clustering
(KM) developed by MacQueen [52]. It produces intervals that are applied to
sub-partitions of the instance space. KM is a non-hierarchical procedure that
partitions observations into k non-overlapping bins using an algorithm that produces
groups of objects with a high degree of similarity within each group and a low
degree of similarity between groups. A more robust variant application of k-means
clustering is k-medoids clustering, which uses the most centrally located objects
as the representative of a cluster instead of shifting centroids according to the
computing of the mean of each cluster [41]. The most common realization of k-
medoid clustering is the Partitioning Around Medoids (PAM) algorithm [63]. It
starts by arbitrarily selecting k objects as the medoids and associating each remaining
object to the closest medoid, then iteratively swapping each medoid and non-medoid
if the recomputed configuration decreases until a pre-defined criterion is met. We
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employ this probabilistic naturalized method to discretize the continuous phenotype
of interest in clinical data. How to find the optimal number for k to perform clustering
will be covered in section 3.2.
Holte describes an error-based supervised discretization method using error counts
to refine the partition breakpoint estimation of each bin [37]. This method, referred to
here as 1RD, sorts the attribute into ascending order and greedily divides the feature
into bins, each containing only one instance of a particular class. The inherent danger
of such a scheme is that it may lead to one bin for each instance. To circumvent this
problem, the algorithm is constrained to formed bins, excluding the upper most bin,
with a minimum number of instances of a particular class. Any specific bin, therefore,
can comprise more than one class label and boundaries will not be continually divided,
leading to overfitting. The partition moves to the right to add an observed value to a
particular bin until it contains at least six instances of a class label, and it continues
until the instance to be considered is not part of the majority class label. Empirical
analysis of 1RD on a number of classification tasks suggests that a minimum bin size
of six performs the best [26].
The last discretization method we will consider is based on the algorithm of Fayyad
and Irani [31], which uses entropy measures to evaluate candidate splitting points
with the Minimum Description Length (MDL) as the stopping rule. This supervised
algorithm utilizes the class information entropy of candidate partitions to select bin
boundaries for discretization. Class information entropy is a measurement of the
unpredictability of information content, and it measures the amount of information
needed to identify which classes of a set that a particular instance belongs [10]. The
concept of entropy will be covered in section 3.3 with regards to feature selection.
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Information entropy considers one large interval containing all known values of a
feature and selects a binary discretization boundary by finding a single boundary that
minimizes the entropy function over all possible boundaries. This entropy function
is then applied recursively to split both of the partitions into smaller subintervals
until the stopping criterion MDL is achieved, thus leading to a discretization of the
continuous attribute into multiple intervals. This method is performed as a step of
data preprocessing process (see section 4.1.2) to discretize the value of each gene
expression profiling into discrete intervals.
2.2 Current Statistical Methods for the Analysis
of High-Dimensional Survival Data
Over the past decade, the revolution in biomedical technologies has changed the
face of biomedical research [79, 8, 23, 67]. Biologists are now able to conduct more
experiments at the same time in less time-consuming ways, which has resulted in
the increasing availability of genetic data, a better understanding of the biological
mechanics of diseases such as cancer, and opportunities for secondary uses of heath
information.
As a result of this breakthrough in modern genomics technology, many studies on
survival have emerged [79, 47, 23]. In the context of survival data, the number of
features (p), for instance gene expression profiling, significantly exceeds the number of
observations (n), namely patients. This type of data requires considerable amendment
in order to apply the aforementioned classical statistical methods [4, 13]. In addition
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to biological data, clinical data, including survival outcomes of the same observations,
are also available. Collett provides a good overview and a variety of examples on
survival data [19]. Many studies have resulted in the successful identification of
previously unknown subtypes of cancer as well as stratifying newly diagnosed patients
into subtypes based on short- or long-term prognoses and predicting survival time
[47, 22, 11, 6].
A number of existing approaches in the literature are applicable for distinguishing
patients into subtypes, which are associated with patient survival time and response
to treatment, based on survival data in high-dimensional setting are presented below.
These methods fall into three broad categories: unsupervised learning techniques that
consider only microarray data; supervised learning approaches, which are exclusively
based on clinical data; and, more recently, semi-supervised procedures that take both
microarray and clinical data into account for the determination of cancer subtypes.
2.2.1 Terms and Notation
High-dimensional data is complicated by a number of factors, such as latent class
label structure and the small n large p problem for microarray data concerning the
same cancer diagnosis [27]. In addition to the terminology presented thus far, several
other useful terms and notations can be defined. Let X denote an n × p matrix
on a sample of n observations with p features each. Each observation X i ∈ Rp is
a p × 1 vector of features, and the associated survival information (i.e., survival
time si= (ti, δi), tumor size, patient gender, etc.) is also accessible. The survival
time, ti, is the time from disease diagnosis to the last follow-up. If the observation is
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complete, δi = 1, and if it is censored, δi = 0; that is, δi = 1 if observation i failed
at time ti, and if δi = 0, the observation i survived to at least time ti or was lost
to follow-up. In the context of the current survival analysis, subgroup Ci can be
defined as the subtypes associated with patient survival time. The objective of these
approaches therefore depends on the available dataD = (X, S) in order to identify the
subgroup membership, C, which is both biologically meaningful and correlated with
clinical outcome. In contrast to the unsupervised learning technique and supervised
learning approach based on either X or S to guide the identification of subgroups, a
semi-supervised procedure takes advantage of both X and S to determine subgroup
discovery.
2.2.2 Unsupervised Approach
Generally speaking, the problem with unsupervised learning lies in attempting to
identify the latent structure in unlabeled data. With regards to the analysis of high-
dimensional survival data, the objective is to unseal the concealed gene expression
profile structure that define cancer subtypes, which differ at the molecular level and
are associated with survival outcome. This knowledge is then used to diagnose a future
group of patients in terms of their subgroups. Survival information is not taken into
account during the determination of subgroup membership (i.e., the subgroups are
identified using only the gene expression data). Once subgroup membership, C, has
been determined according to the training dataset, X0, a classifier can be trained
according to the assigned subgroups C1, C2, ..., Cn in combination with testing data
set, X1, to predict the subgroup membership of a future group of patients. Figure 2.7
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depicts the general procedures of unsupervised learning techniques.
Figure 2.7: The general steps that constitute unsupervised learning approach
Approaches to unsupervised learning include hierarchical clustering [28], k-means
clustering [72], and model based clustering [32] to name a few. For an overview
of unsupervised learning techniques, see Clifford et al [18] or Gordon [34]. Of
these techniques, hierarchical clustering has been used to identify cancer subtypes
associated with survival outcome in a number of different studies [25].
The basic principle behind hierarchical clustering is to use a metric of similarity
between each individual observation to group observations into different clusters.
The measure of similarity is based on all or a selected subset of the features chosen
independent of the phenotype of interest. Thus, objects in the same cluster are
similar, and they are dissimilar to different clusters. A clustering dendrogram is then
used to define subtypes of patients. Figure 2.8 illustrates the clustering dendrogram
for a publicly available renal cell dataset [85], which is also used to test our proposed
approach in Chapter 4. The p-value for the log-rank test is 0.0479, which is predictive
of survival (at p = 0.05). However, there is no guarantee that the subtypes this
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approach obtains will always be correlated with the clinical outcome because survival
information is ignored when determining the subgroup membership.
Figure 2.8: Hierarchical clustering dendrogram of renal cell data
2.2.3 Supervised Approach
The second approach for identifying cancer subtypes that differ in survival progress
is supervised learning. Supervised learning techniques use clinical data exclusively
in the determination of subgroup membership. In the context of survival time,
observations can be partitioned into a “low-risk” or a “high-risk” subgroup based
on whether patients are still alive at a certain follow-up time. The determined
subgroups C1, C2, ..., Cn can be used in training a classifier that predicts the subgroup
34
membership of a future group of patients. Alternatively, information such as whether
a patient’s tumor has metastasized or other available clinical thresholds can be used
to develop procedures to predict subgroup membership [11]. This approach has been
used to identify cancer subtypes in a number of studies [80, 81]. Figure 2.9 depicts
the overall process for a supervised learning approach.
Figure 2.9: The overall process for a supervised learning approach
Once observations in the training data have been labeled with subgroup membership,
(i.e., C1, C2, ..., Cn), this information is used to diagnose future patients. For instance,
patients are partitioned into a low-risk or high-risk subgroup based on the observed
median survival time as the clinically relevant threshold. The trained median survival
time function can then be used for mapping future instances into one class or the
other. An optimal scenario occurs when new examples are correctly assigned to their
actual subgroups. This requires the trained classifier to generalize from the training
data and apply its knowledge to an unseen situation in a “reasonable” way. However,
since supervised learning by definition does not involve X guiding the identification
of subgroups, the resulting subgroups may lack reasonable biological meaning.
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Suppose there are two pre-specified subtypes associated with the same cancer
diagnosis, and patients with subtype 1 live somewhat longer than those with subtype
2, as shown in Figure 2.10. Since there is a significant overlap between the two
subgroups with respects to survival time, simply assigning observations to the low-
risk or high-risk group based on the median survival time would result in an incorrect
determination of the subgroups for unseen patients. Therefore, the diagnosis of any
future patients based on this model would be questionable. More accurate prediction
can be made by including microarray data in the determination of subgroup and by
developing a model that can predict which subtype is present in a future diagnosis.
Figure 2.10: Two subtypes of cancer diagnosis with significant overlap
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2.2.4 Semi-Supervised Approach
As previously stated, the exclusive use of either microarray data or clinical data in
unsupervised and supervised methods for the identification of subgroup inhibits both
the discovery of biologically meaningful subgroups and the likelihood of accurately
predicting survival outcome. To overcome these difficulties, the semi-supervised
approach uses both X and S to guide the determination of cancer subtypes facilitating
the identification of biologically meaningful classes that are also correlated with
clinical outcome. Here, four universal steps shared by semi-supervised approaches
are first discussed, followed by descriptions of two canonical semi-supervised learning
techniques, namely, semi-supervised clustering [3] and the semi-supervised risk index
method [5].
2.2.4.1 The General Approach to Semi-Supervised Learning
The four universal steps of semi-supervised learning are shown in Figure 2.11.
1. Data splitting: The first step to any semi-supervised learning approach is
preprocessing the raw data. After this step, the data is partitioned into two
sets: a training set tasked with inferring the function, and a testing set used
for validating whether the mapping of new examples based on the inferred
function is “reasonable”. Sometimes the partition is a natural one; this occurs
when data is obtained as a collection of training and testing data. In the vast
majority of cases, however, data is collected as one complete set without having
a training and testing set in mind. Therefore, the random division of data into
calibration and validation sets is needed. The random splitting should preserve
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Figure 2.11: The general procedure of semi-supervised learning
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the overall class distribution of the data, although conventions vary in terms of
the proportion of samples allocated to calibration and validation sets. A half-
and-half allocation is preferred because it balances poor predictive performance
results from overfitting and an inadequate number of samples in the validation
set [61]. In Chapter 4, this is how we split data for the purpose of calibration
and validation.
2. Subgroup assignment based on supervision: The purpose of this phase
is to assign subgroups to the observations in the training set obtained from
the previous data splitting step. This action distinguishes the semi-supervised
approach from supervised and unsupervised methods. A list of significant
features is first identified apropos of the phenotype of interest, and the
assignment of subgroups is based on this subset of features. By making use
of both X and S to determine subgroups, the identified subgroups are both
biologically meaningful and associated with the primary phenotype of interest.
3. Determining class subgroup in the testing set: The function inferred
from the training set is then used for mapping “unseen” examples in the testing
set into the identified subgroups. The two canonical semi-supervised learning
techniques apply different inferred functions. The Clustering-Cox method
employs the “nearest shrunken centroids” techniques [75] to categorize future
observations into the appropriate subgroups. On the other hand, the Risk Index
approach is based on percentile cut-off points to classify future examples into
suitable subgroups. Specifically, the risk index is created from the cumulative
effects of all the identified features’ univariate Cox score of each observation.
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These two methods will be discussed in detail in sections 2.2.4.2 and 2.2.4.3.
4. Testing the association with phenotype: In an ideal scenario, the inferred
function correctly assigns new examples in a testing set to their intrinsic
subgroups. This requires the inferred function to generalize from the training
data and apply this knowledge in a “reasonable” way. The level considered
reasonable can be determined by testing the association between subgroup
prediction of examples in the testing set and the phenotype of interest. Methods
for testing the association will depend on the nature of the primary phenotype.
In this thesis, the phenotype is a time-to-event outcome (i.e., survival time),
thus a log-rank test and resultant p-value can be used [2].
2.2.4.2 Clustering-Cox Method
Bair and Tibshirani proposed a semi-supervised approach to identify cancer subtypes
and predict patient survival [3]. Unlike the fully unsupervised method, where all
features are selected for clustering regardless of the phenotype, this method’s guiding
principle is to apply unsupervised clustering techniques to a list of identified genes
that correlate with the primary phenotype of interest. In the case of survival data,
the method is carried out as follows.
First, a subset of genes actually associated with survival must be compiled. The
most widely used and straightforward way to identify features that individually
correlate with survival is to use univariate Cox scores [43]. For each feature, a
univariate Cox proportional hazards model is fitted. The feature selection with Cox
score (FSCS) quantifies the correlation between gene expression level and patient
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survival as follows:
Sj =
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where xj represents each feature, and the other notations are identical to those
described in Equation 2.5 (see section 2.1.2.3).
A large Sj indicates that feature j predicts survival well. A positive value of
the Cox score suggests that over-expression of that gene is correlated with increased
survival, and a negative value indicates decreased survival. Univariate Cox scores are
calculated for each gene in the expression data, and only genes with a Cox score that
exceeds a certain threshold are considered for clustering purposes.
Once the dimensions of the gene expression data have been reduced using the
Cox score, the reduced data is used to identify subgroup. The existing clustering
techniques can then be applied to form clusters. Within each identified cluster,
patients share small, pairwise distances. As soon as subgroup is available, supervised
learning is used to infer a function from training data to match future patients with
appropriate subgroups. The supervised learning technique employed in this study is
the nearest shrunken centroids procedure of Tibshirani et al. [75], which calculates
the mean expression of each gene with each class and then shrinks these centroids
toward the overall mean for that gene by a fixed quantity.
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2.2.4.3 Risk Index Method
We now discuss another representative semi-supervised method proposed by Beer
et al., which involves the prediction of future examples using a risk index inferred
function [5]. The objective of the method is to assign a diagnosis to a future patient
as described by the cumulative effects of the significant genes of the patient. The
state or quality of significance is numerically measured from the risk index and the
selected percentile cut-off point determines the assignment of subgroup.
First, a risk index must be created according to the cumulative effects of the
selected genes of the patients in the training set. The selected genes are correlated
with the primary phenotype of interest, and the selection is based on the FSCS
[43]. The selected genes are individually fit with a univariate Cox proportional
hazard model, and then a linear combination is constructed from the subset of
genes by multiplying the estimated regression coefficients by their corresponding gene
expression values and adding the results. This linear combination defines the risk
index and evaluates the association of the identified genes with the phenotype.
The next step is to examine the proper cut-off point based on the distribution of
risk index values calculated in the training set. Percentile, a common way of reporting
scores from norm-reference tests, is then used to categorize patients into different
groups. Note that it is difficult to estimate or judge the number of identified genes and
the related percentile that have the best overall association with survival. Therefore,
a continuum of cut-off points for different numbers of selected genes is examined in
order to produce an optimal inferred function. Using the risk index function in the
training set, future patients in the testing set are placed in the appropriate subgroups.
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Both semi-supervised clustering and the risk index based-method make use of X and
S for the identification of cancer subtypes and by doing so guarantee the identified
subtypes are biologically meaningful and will strongly predict survival time. These
two methods yield satisfactory results in many datasets [85, 11, 5].
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Chapter 3
Using the Machine Learning
Approach for High-Dimensional
Survival Data
This chapter outlines the machine learning approach to feature selection and the
survival prediction of patients from high-dimensional survival data. Two new methods
designed to cope with censoring and to discover latent class memberships are first
introduced, followed by the details of the proposed approach.
3.1 Coping with Censoring
Classical statistical methods account for censoring with the Cox model, which keeps
censoring individuals in the risk set along with other individuals who have not yet
experienced the event of interest [43]. In preference to standard statistical methods,
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we use k-nearest neighbor based on clinical parameters that are truly associated
with survival time to cope with patients’ censoring. These clinical parameters are
selected using penalized logistic regression and the penalized proportional hazards
model with the Expectation Maximization (EM) algorithm. They are then used to
estimate censored survival time.
3.1.1 Selecting Clinical Parameters that Associate with
Phenotype of Interest
A new survival time associated for each censored individual is computed according to
the proximity of clinical data to observations. Variable selection in the proportional
hazards mixture cure model based on penalized likelihood is used to select important
clinical covariates that are associated with the phenotype of interest (i.e., patient
survival time) [50].
Let p(t|z) be the probability of being cured given a covariate vector z = (z1, ..., zq)’,
S (t|x) be the survival function for uncured patients, conditional on x = (x1, ..., xm)’,
and  = p (ti, δi, xi, zi, yi) represent the complete data for the ith individual, i
= 1, ..., n. As specified in Chapter 2, the observed survival time that is possibly
censored is given by ti; δi is the censoring indicator; zi and xi are covariates in the
incidence and latency parts of the function, respectively; and yi is an indicator of
cure status, where yi = 0 if the patient is uncured and yi = 1 if the patient is cured.
Here, there is missing information because if δi = 1, yi = 0, but yi can either be 1 or
0 when δi = 0. Therefore, y is partially missing information and the EM algorithm
is appropriate for estimating the parameter of interest Θ = (xi, zi, S0 (t)), where
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S0 (t) is the corresponding baseline survival function with respect to h (t). Given ,
the complete likelihood function of proportional hazards mixture cure model is
n∏
i=1
p(zi)
1−yi [1− p (zi)]yih(ti|xi)δiyiS(ti|xi)yi (3.1)
The EM algorithm can be implemented based on the complete likelihood function
Equation 3.1. To select significant clinical parameters, we add a Lasso penalty to
the likelihood function to form the penalized likelihood function. The new penalized
complete log likelihood function can be written as
l (γ, β; ) =
n∑
i=1
(1− yi)log[p (zi) ] + yilog[ 1− p (zi)]
+
n∑
i=1
yiδilog[h(ti|Y = 1, xi) ] + yilog[S(ti|Y = 1, xi)]
+ nλ1j
q∑
j=1
|γj| + nλ2k
m∑
k=1
|βk|
(3.2)
where λ| · | is the Lasso penalty function and λ = (λ11, . . . λ1q, λ21, . . . λ2m) is the
tuning parameter, which can be chosen via GCV as discussed in Chapter 2.
For a selected value of λ, the EM first calculates the expected value of the penalized
log likelihood function with respect to the conditional distribution of yi, given the
observed data and current estimates of parameters (γr, βr, Sr0 (t)). In order to
accelerate the estimation process, we assign values to the first estimates that maximize
the un-penalized log-likelihood. The logarithm of the penalized complete likelihood
function can be expressed as lc (γ, β, S0 (t) ; ) = lc1 (γ; ) + lc2 (β, S0 (t) ; ),
where
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lc1 (γ; ) =
n∑
i=1
(1− yi)log[p (zi) ] + yilog[ 1− p (zi)] + nλ1j
q∑
j=1
|γj| (3.3)
lc2 (β, S0 (t) ; ) =
n∑
i=1
yiδilog[h(ti|Y = 1, xi) ] + yilog[S0(ti|Y = 1, xi)] + nλ2k
m∑
k=1
|βk|
(3.4)
The conditional expectation of yi will be enough to complete this step because
both (3.3) and (3.4) are linear functions of yi. The expectation of E (yi| γr, βr, Sr0 (t))
can be written as follows:
w
(r)
i = E (yi| γr, βr, Sr0 (t)) = δi+(1− δi)
[1− p (zi)]S0 (ti|Y = 1, xi)
p (zi) + [1− p (zi)]S0 (ti|Y = 1, xi) |γ
r, βr, Sr0(t)
(3.5)
It is clear that w
(r)
i = 1 if δi = 1 and w
(r)
i is the probability of uncured patients if
δi = 0. The second part of w
(r)
i actually represents the conditional probability of the
ith individual remaining uncured.
The M-step in the (r+1)th iteration is to maximize (3.3) and (3.4) with respect
to Θ. The parameters in function (3.3) can be maximized using a penalized logistic
program to obtain γr+1. Likewise, the function (3.4) is the penalized log-likelihood
function of the PH model with the additional offset variable logw
(r)
i with fixed
coefficient 1. The Lasso-penalized clinical parameter selection is made through the
quadratic approximation procedure [36]. In addition, if prior biological knowledge
shows that a certain variable has a known involvement in the cancer process, we can
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remit the penalty on the variable by setting the corresponding tuning parameter in
λ to zero. For example, we do not place any penalty on the intercept because it is
always in the logistic regression part. Note that the estimation of γ and β do not
depend on the assumption of the distribution [48].
3.1.2 Estimating Censored Survival Time
After a list of significant clinical parameters has been compiled, we approach this
problem with the intuitive idea that things of a kind come together. Specifically, we
compute the new survival time with the selected clinical covariates with regards to the
proximities among them. The definition of “proximity” we employ here is a variant
of the Euclidian distance such that it is applicable to numerical clinical variables as
well as nominal clinical variables [54]. The expression for proximity is
d (x, y) =
√√√√ p∑
i=1
φi (xi, yi) (3.6)
where φi() is the distance between two variables defined as follows:
φi (v1, v2) =

1 if i is a nominal variable and v1 6= v2
0 if i is a nominal variable and v1 = v2
(v1 − v2)2 if i is a numeric variable
(3.7)
The ten uncensored neighbors with the smallest proximities are selected to
compute the event time of interest associated with the censoring time. In addition,
weights are assigned to the contributions of the neighbors, such that the nearer
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neighbors contribute more to the average than the more distant ones. The Gaussian
function is used to obtain the weights [62]. If the neighbor is positioned at a distance
d away from this censored observation, then the weight of this uncensored survival
time is
w (d) = e−d (3.8)
3.2 Identify Latent Class Membership
As stated in Chapter 2, in order to identify biologically meaningful subtype
membership that accurately determines the subtypes of future patients, features need
to be chosen respective of the phenotype of interest. Current statistical approaches
exclusively rely on the Cox score category to identify subgroup [47, 22, 11]. We
instead propose to discretize the survival time of patients; thus, sets of patients with
measured similarities will share an identical class label, while this value is minimized
between patients with different class labels.
A prerequisite for applying the partitioning technique to discretize the continuous
phenotype of interest in clinical data, which applies to the probabilistic naturalized
PAM algorithm [63] used here, is the optimal choice of the number of splitting bins
from the data. “The best k” of clusters to be formed should allow an appreciation
of the relative quality of the clusters and overall structure of the data [14]. There
are methods for choosing “the best k” for different discretization algorithms, such as
the heuristic method from Dougherty [26], in which k = max {1, 2 ∗ log l}, where l is
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the number of distinct observed values for the attribute being partitioned. Another
method, proposed by Crescenzi [21], relies on the knowledge of data properties to
determine the “natural” number of clusters. However, the degree to which these
apriori clustering schemes reflect a specific dataset is still under-investigated in the
literature [7].
While the aforementioned methods specify the number of clusters to be formed
ahead of the clustering process, we apply another approach, silhouettes [66], to
select the optimal number of clusters in a partitioning by evaluating the validity
of the produced clustering. More specifically, the silhouettes method interprets the
clustering results and selects the best clustering scheme with the most compact and
clearly separated clusters regardless of the clustering algorithm used.
3.2.1 Construction of Silhouettes
Suppose that there are n objects to be clustered. The clustering technique assigns
these n objects into k clusters such that objects within the same cluster bear more
resemblance to each other than to those in other clusters. Although it is easy to
construct clusters of data based on the clustering algorithm, little is known about
the number of “natural” clusters that are actually present. The silhouettes method
is designed to provide additional guidance and deeper insight into an optimal choice
of partition.
Silhouettes are constructed from the partitions obtained through a selected
clustering algorithm, as well as the metric of collected proximities between each
individual object. Assuming the data have been clustered via a certain technique,
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silhouettes are constructed such that the value s(i), which measures how well an
object i has been classified, is defined for each object i. These numbers are then
combined to form silhouettes representing each cluster to provide an overview of data
configuration. The computation of s(i) concerning a specific datum i in the dataset
consists of calculating the average dissimilarities of i to the objects in the same group
as i and those in a different group. These two dissimilarities, denoted a(i) and c(i),
can then be compared to give a quantitative measure of how well i is assigned to
its home group relative to other groups. Let A be the cluster to which i has been
assigned, where A contains other objects apart from i (not a singleton); cluster C is
any distinct partition from A; and B is the cluster in which i is not a member (i.e., the
neighbor cluster of object i) and holds the lowest average dissimilarities c(i). These
dissimilarities are formulated as follows:
a (i) = average dissimilarities of i to all other objects of A
c (i) = average dissimilarities of i to all other objects of B
b (i) = minimun d (i, C) , C 6= A
(3.9)
The neighbor of i can be viewed as the second-best choice for object i, that is, if
cluster A is discarded, then cluster B is the next best fit. It is worth mentioning that
the construction of silhouettes depends on the availability of clusters distinct from A.
Therefore, the number of attained clusters, k, is at least greater than one. The value
s(i) is obtained by combining a(i) and b(i) as follows:
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s (i) =

1− a (i)/b (i) if a (i) < b (i)
0 if a (i) = b (i)
b (i)/a (i) − 1 if a (i) > b (i)
(3.10)
As we can see from this formula, the value of s(i) for each object i ranges from
-1 to 1, and remains invariant when all the original dissimilarities are multiplied by
a positive constant. Consequently, a dissimilarity of 4 is considered twice as large as
a dissimilarity of 2.
A high a(i) value indicates a strong dissimilarity between datum i and its own
cluster, whereas a small a(i) value suggests that it is well classified within its cluster.
Moreover, a large b(i) value implies that the next best fit is poorly matched to datum
i. Thus, for s(i) to be close to 1, we require the “within” similarity a(i) to be much
smaller than the minimum “between” similarity, b(i). This suggests that object i
resembles more objects within the same cluster than those in other clusters, giving
strong evidence that i has been assigned to the most suitable cluster. On the other
hand, if s(i) is close to -1, then, by the same logic, datum i generally lies much closer
to the neighboring cluster than its home cluster. In this circumstance, assigning
object i to the home cluster instead of a neighboring cluster would be questionable.
The intermediate is observed when object i lies equally far away from cluster A and
B, giving two roughly identical values of a(i) and b(i), and resulting in an s(i) close
to zero. Therefore, it remains uncertain which cluster is the best choice for object
i. In the special case where A is a singleton, the value of s(i) is neutrally set to
0. When the data consist of similarities, the silhouettes method can be used with a
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slight modification:
s (i) =

1 − b
′(i)/
a
′(i) if a′ (i) > b′ (i)
0 if a′ (i) = b′ (i)
a′ (i)/b′ (i) − 1 if a′ (i) < b′ (i)
(3.11)
where b′ (i) = maximum d′ (i, C) , C 6= A.
After computing the quantities s(i) from either similarities or dissimilarities, the
construction of silhouettes is possible. The silhouette of a certain cluster plot contains
s(i) for all objects belonging to this cluster ranked in decreasing order. Its height
equals the number of objects contained in this cluster. The length of each line printer
is proportional to the corresponding s(i). Therefore, the silhouette provides a succinct
graphical representation of how well each object lies within its cluster, that is, the
wider a silhouette, the larger the s(i) value, and the more pronounced the cluster.
The final step of the construction is to incorporate the silhouettes of different clusters
into a single plot. The entire clustering is displayed one after another, which enables
us to distinguish appropriate clusters from unnatural ones and provides an evaluation
of clustering validity.
3.2.2 Selecting the Appropriate Number of Class Label
We illustrate the silhouettes method using the dataset of Beer et al. [5], which
is described in the description of datasets section. In Figure 3.1, the silhouettes
representing k = 2 for the clustering of lung cancer data is shown. Below the plot,
there is a vertical scale ranging from 0.0 to 1.0 with steps of size 0.2. The computed
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quantity s(i) of each patient corresponds to the markings on the scale. The second
silhouette is higher than the first because the second cluster contains 61 patients
compared to 25 in the first cluster. The rightmost section of the plot reflects the
average s(i) for all objects i in a cluster (i.e., the average silhouette width of that
cluster) and measures how tightly grouped the data is in the cluster. Both silhouettes
in Figure 3.1 are rather wide, contributing to high average silhouette widths that
imply a relatively strong clustering structure. If we compare these two cluster results
from the same partition, the second cluster is tighter and better separated due to
its wider average silhouette width. In particular, the patients in the second cluster
possess the largest s(i), which means that it is classified with the least amount of
doubt.
Figure 3.1: Silhouettes of clustering with k = 2 of the lung cancer data.
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For each individual patient, the silhouettes also reveal the index of the cluster to
which it belongs, the index of its neighboring cluster, and the exact numerical value
of s(i); however, this information is omitted due to the limited space on the plot. If
the computed s(i) value is close to zero, the length that corresponds to the marking
on the scale becomes zero as well. Thus, the object lies on the border of two natural
clusters. In the case of negative values, the length of the line printer is the absolute
value of s(i). We can identify the “misclassified” object by looking at the sign of
s(i). Alternatively, because the silhouette is plotted in decreasing order, any objects
ranked below an object with a s(i) value of 0 are “misclassified” cases. For these
objects, the longer its silhouette length, the more naturally it fits into its neighboring
clustering. We can improve the clustering results by moving these objects to their
neighbors.
The very last number, listed below the scale, is the average silhouette width for the
entire dataset. This number, denoted by s¯ (k), plays a key role in selecting the natural
value of k, as it measures how appropriately the data has been clustered. Figure 3.2
shows silhouette plots of the lung cancer data for k with the four highest average
silhouette widths after computing average silhouette widths for PAM partitions
corresponding to all possible values of k. In general, different k varies in average
silhouette width. The silhouettes should appear as wide as possible for a natural
value of k, thus one way to choose k appropriately is to select the value that yields
the maximum average silhouette width. We see that the computation of average
silhouette widths for all possible k returns a highest average silhouette width value of
0.72 when k = 2, so we select k = 2 to discretize the continuous time space specific
to this lung cancer dataset.
55
Figure 3.2: Silhouettes plots of the lung cancer data, for k with 4 top average
silhouette widths
The aforementioned procedure can be extended to other datasets by computing
the maximal average silhouette width for the entire dataset, defined as the silhouette
coefficient (SC),
SC = max s¯ (k) (3.12)
where the maximum is selected over all k for which silhouettes can be constructed.
In the context of our proposed approach, which seeks to identify meaningful
survival subtypes that accurately predict outcome, the value range of k is set to less
than or equal to 10 because there rarely exists a cancer with more than 10 subtypes
[6]. The SC offers a useful measure of the relative quality of the clusters that have
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been discovered by the classification algorithm. Table 3.1 gives an interpretation of
the SC [42].
Table 3.1: Interpretation of the silhouette coefficient (SC)
Silhouette coefficient Interpretation
0.70 - 1.00 A very clear structure has been found
0.50 - 0.69 A reasonable structure has been found
0.26 - 0.49 The structure is weak and could be artificial;
extra improvement or alternative method is needed
<= 0.25 No substantial structure has been found
Indeed, an SC close to 1 means the data is officially clustered, while a low SC
suggests that an alternative method of data analysis is more appropriate. For the
lung cancer dataset, s¯ (k) = 0.72, which is indicative of a strong structure. One
scenario that requires special attention is when certain far-enough clusters contain
only a single object or relatively few objects. Such singleton clusters are regarded as
outliers. Depending on the context and the task at hand, we can set aside the outliers
for further investigation and rerun the clustering algorithm on the remaining data.
The overall average silhouette width as well as the graphical output itself assist us in
determining the natural number of clusters within a dataset.
57
3.3 Feature Selection for High-Dimensional
Survival Data
As mentioned previously, current methods of survival analysis with high-dimensional
data use the Cox score to quantify how well each feature predicts survival, and
the selected features are candidates for follow-up experiments [43]. This selection
process is based on the association between each individual feature and the survival
outcome. The computation also requires iteratively fitting a Cox model for each
feature, which can be computationally inefficient when the number of features is
very large. Also, that model does not have the ability to reduce relevancy; thus
it can potentially select highly redundant features. It is well known that when the
dimension is high, redundant features can cause over-fitting, which jeopardizes the
generalization capability. Many feature selection methods in machine learning, on
the other hand, can identify relevant features as well as redundancy among relevant
features in an efficient manner.
Selecting an informative subset of features from an existing feature space plays
an important role in any machine learning applications. This is even more so in our
context where the class label is itself one of the learning targets. As a result, un-
informative features can produce overfitting with more unpredictable results in our
context than in applications where the class labels are given a priori. Therefore, the
appropriateness of the employed feature selection method is crucial in success of the
approach and should be adopted in extreme care.
Feature selection in machine learning falls into two broad categories: the wrapper
method [44] and the filter method [24]. In the wrapper method, the feature subset
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selection algorithm conducts a search for a good subset using the induction algorithm
itself as part of the function evaluating feature subsets. It enforces a straight order
and may be stopped at a local maximal. A typical example of the wrapper method
is Gradient Boosted Feature Selection (GBFS) [83]; GBFS starts with pre-specified
parameters, then iterates using embedded greedy CART algorithm to minimize the
selected impurity function for learning regression tree until the stopping condition is
met. Unlike a wrapper approach, a filter method defines a metric that, independently
of any learning algorithm, measures the relevance of each feature with the outcome.
Many sophisticated filer methods also incorporate redundancy reduction mechanisms.
All these proceed without involving any learning algorithm. An example of a filter
method is Fast Correlation-Based Filter (FCBF) [84]; FCBF first removes and ranks
features according to predominant correlation. It then selects a subset of features
according to a user-specified threshold. Different from GBFS which assumes that one
can pre-process the data with limited-depth trees, FCBF is free of data assumption.
In our approach, since it plays a pivotal rule, feature selection should serve as an
independent component, without being influenced by the bias of any specific learning
algorithm. Furthermore, the feature selection methods used by many existing works
in predicting patient survival are based on Cox scores, which is essentially a filter
method. Therefore, using filter also in our context can make comparison with these
works more meaningful. In summary, we prefer filter in our work, and will use
FCBF for feature selection due to its effectiveness in handling both relevance and
redundancy, as well as its pronounced efficiency.
The FCBF selects significant features for prediction based on correlation analysis.
Two information-theoretical concepts, entropy and information gain, are chosen to
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measure the correlations. The first concept, entropy, is a measure of the uncertainty
of a random variable [10], where the entropy of a variable X is defined as
H (X) = −
∑
i
P (xi) log2 (P (xi)) (3.13)
and the entropy of X after observing values of another variable, Y, is defined as
H (X | Y ) = −
∑
j
P (yi)
∑
i
P (xi| yi)log2 (P (xi | yi)) (3.14)
where P (xi) are the prior probabilities for all values of X, and P (xi| yi) are the
posterior probabilities of X given the values of Y. The amount by which the entropy
of X decreases provides additional information about X from Y and is called
information gain [61].
IG (X | Y ) = H (X) − H (X | Y ) (3.15)
If we have IG (X | Y ) > IG (Z | Y ), it means a feature Y is more correlated to
feature X than to feature Z. In reference to this work, X and Z are genes to be selected
and Y can either be a gene or the class label estimated from the discretization of time
space. When Y is the feature, IG measures the redundancy between these two genes.
Alternatively, IG quantifies the predictive ability of the gene in class memberships.
However, information gain is biased in favor of features with more values. The
values also have to be normalized to ensure they are comparable and have the same
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effect. Therefore, symmetrical uncertainty (SU) [60] is introduced:
SU (X, Y ) = 2
[
IG (X | Y )
H (X) − H (Y )
]
(3.16)
The theory of the FCBF algorithm is based on the aforementioned concepts and
is executed as follows:
1. Calculate the SU value for each feature related to the classification;
2. Eliminate irrelevant features according to a predefined threshold SU value in
order to build a list of relevant features, Slist, based on their SU values and
appearing in descending order;
3. Calculate the SU value for each feature in Slist (except for Fr itself) related to
Fr, which is the first feature of Slist;
4. Eliminate redundant features in Slist according to a predefined threshold SU
value and take the remaining feature beside Fr as the new reference;
5. Repeat steps 3 and 4 until a target number of features is selected or there are
no more features to be removed from Slist.
In general, FCBF first decides whether a gene is relevant to the survival outcome,
and then determines whether the gene is redundant when considering it in relation
to other relevant genes. The computation of SU is also much more efficient than
iteratively fitting a Cox model for each feature.
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3.4 Classification
After generating a list of features that correlate with the phenotype of interest,
a classifier can be applied to this subset of genes to determine which subtype is
present in a future patient. We use Na¨ıve Bayes and Decision Tree for their known
effectiveness and applicability.
3.4.1 The Na¨ıve Bayes Classifier
In machine learning, the Na¨ıve Bayes classifier (NB) is a probabilistic classifier
using Bayes’ theorem [68]. Instead of assigning an instance to a certain category,
it calculates the probability of this instance belonging to each category and chooses
the largest one. Suppose there are m classes, C = {C1, C2, . . . , Cm}, and a given
instance with feature X = {X1, X2, . . . , Xm}, then the posterior probability that
this randomly given instance belongs to a class Ci is P (Ci | X) = P (Ci, X)/P (X).
Using Bayes’ theorem, the Bayes’ classifier can be represented as follows:
P (Ci | X) = P (X | Ci)P (Ci)
P (X)
(3.17)
That is, the classification function assigns each instance to the class that has the
highest probability of containing this instance. In practice, there is interest only in the
numerator of the fraction since P (X) is the same for all Ci, and the Bayes’ criterion
is equivalent to classifying X in the class that maximizes P (X | Ci)P (Ci).
We choose the NB algorithm mainly for its simplicity and effectiveness. In
addition, the NB classifier is general-purpose and good enough for most applications,
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even if the NB assumption does not hold [70, 51]. Therefore, it is one of the first
methods to try in a classification problem.
3.4.2 The Decision Tree Classifier
Another type of commonly used classifier in the field of machine learning is the
decision tree (DT) classifier [68]. A decision tree represents classification rules and
is a flowchart-like structure in which each internal node is a test on some attribute
values; each branch is one of the outcomes of the test, and each leaf node is a class
or a group of classes. The algorithm begins with the original set S as the root node
and iterates through every unselected attribute of S. The “best” attribute is chosen
at each iteration to split the set S into subsets of data. The “best” commonly means
the homogeneity of the target attribute within the subset and can be measured with a
myriad of metrics, such as the information gain of that attribute. The iteration stops
when all objects at a node have an identical class label, or when there are no more
attributes to be selected nor examples in the subset. The pseudocode for building
the decision tree is as follows:
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input : S (R1, R2, . . . , RN , X)
// a training data set contains N attributes and all objects X
output: decision tree
begin
while R = ∅ orX = ∅, or all objectives in X have an identical class label
do
for i← 1 to N do
calculate the metric value for Ri;
end
select the attribute with the highest metric value and remove it from R;
create a decision node that splits on the selected attribute;
end
end
Compared to other classifiers, a decision tree can effectively cope with outliers and
nonlinearly separable data due to its non-parametric characteristics and its ability to
recognize feature interactions [65]. Moreover, it is easy to interpret and explain.
In summary, our proposed approach uses both gene expression data and clinical
data to identify latent class membership and to determine which subtype is present in
a future patient. We first discretize the time-space to discover the hidden structure
based on the estimated class label. A list of genes is then selected based on their
association with survival time by using feature selection combined with identified class
label. The selected genes are used to classify patients, and the resulting classification
solution is then applied as the scheme for identifying cancer subtypes. Subtype is
predicted for future patients using the trained classifier.
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Chapter 4
Results and Discussion
This chapter presents an empirical study designed to evaluate the performance of
our proposed method on high-dimensional survival data and a comparison to related
methods reported in the literature. The evaluation is based on feature selection and
patient prediction using two real datasets in addition to simulation data. The “leave
one out” approach is used to further validate experimental results and to maximize
predictive accuracy.
4.1 Experiments on Real-World Datasets
4.1.1 Description of Datasets
Compared with other applications, survival prediction has a unique requirement for
its datasets: a sufficient long-term follow-up of patients. This renders many existing
datasets not being applicable. We hereby selected two benchmark datasets, which are
publicly available and have been used by many existing works for survival analysis
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[22, 11, 3]. The first dataset, the lung cancer dataset, is described in detail by Beer et
al. [5]. Briefly, the gene-expression profiles of 86 primary lung adenocarcinomas were
obtained using the oligonucleotide arrays; there are 7,129 genes. Several clinical
variables, including patient outcome, are available for each patient. The second
dataset, renal cell dataset, consists of conventional renal cell carcinoma (cRCC) data
on 177 patients who underwent radical nephrectomy for cRCC; there are 5,559 genes
[85]. For each of the subjects in the renal cell dataset, gene expression was assessed
in cRCC tissue samples using the oligonucleotide arrays. In addition to the clinical
data, survival outcome was also included. Because the survival data consist of both
clinical data and gene expression data, we discuss the preprocessing of each. This
process is illustrated with the example of lung cancer data, and the process for renal
cell data is in an identical manner.
4.1.2 Data Preprocessing
4.1.2.1 Clinical Data Preprocessing
Clinical parameters that are truly associated with survival time are selected to cope
with censored survival time, as discussed in Chapter 3. As one of the preprocessing
steps, continuous parameters have to be discretized and a numerical representation
is needed for non-numerical variables. Except for survival time, there are ten clinical
covariates available. Sex is a binary covariate indicating whether a patient is male or
female, coded as 1 or 0, respectively. Age is a binary covariate with a value of 1 if
a subject’s age is less than or equal to 50 years old, and 0 otherwise. Nodal status
is a binary covariate for the presence or absence of lymph nodes and is labeled 1 if
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present and 0 if not. Differentiation is a measure of categorical levels of tumor grade
and is coded as 3, 2, and 1 corresponding to well, moderate, and poor, respectively.
The p53 nuclear protein plays an important role in directing the protein into the
nuclear compartment; its label is p53 nucl.accum. and it is assigned a value of 1 if
the status is positive and 0 if negative. Similar to the p53 nuclear protein, KRAS
mutations, which define a distinct molecular subset of the disease, have a status equal
to 1 if positive or 0 if negative. Pack year measures the frequency of smoking: a non-
smoker is coded as 0; fewer than 20 packs per year is regarded as slight smoking and
is coded as 1; moderate smoking of 20 to 60 packs is coded as 2; and deep smokers
who smoke more than 60 packs per year are coded as 3. A list of 86 patients with
these baseline characteristics is given in Table 4.1. Other covariates (e.g., tumor size,
estrogen receptor status and disease stage) are already numerically represented and
well categorized. Therefore, preprocessing of these covariates is not necessary.
4.1.2.2 Gene Expression Data Preprocessing
The representation and quality of the gene expression data affect the success of the
machine learning approach on a given task. However, raw gene expression data
normally presents genes that are not expressed, genes that do not code for any protein,
or genes that are expressed but show minimal variation across the sample. Moreover,
excluding biological variations in gene expression levels that we are actually interested
in, variations due to the measurement process should be eliminated or minimized if
possible.
We employ a two-step method to address these two problems that accompany gene
expression data. First, a variation filter is used to determine transcript abundance
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Table 4.1: Baseline characteristics of the 86 patients in lung cancer study
Factor Number of patients
Sex Male 35
Female 51
Age <= 50 years 8
> 50 years 78
Nodal status Presence 69
Absence 17
Differentiation Poor 21
Moderate 42
Well 23
p53 nucl.accum. - 69
+ 17
K-ras mutation - 46
+ 40
Smoking (pack years) Non- smoker 9
Slight smoker 13
Moderate smoker 38
Deep smoker 26
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and to exclude uninformative genes. Specifically, the dataset as a whole is trimmed
of genes expressed at extremely low levels and with minimal variation across the
sample, that is, genes were excluded if their 75th percentile value was less than
100 or the variance was less than one-fifth of the interquartile range of the whole
dataset. Although potentially resulting in the loss of some information, trimming in
this manner facilitates the success of the machine learning algorithms by reducing
the impact of genes with little or no expression in these samples, leading to groups
of data that can be used to assign biological meaning to the expression profiles. This
step yields 4,804 genes from the initial 7,129 genes in the lung cancer data. Next,
the resulting gene expressions are centralized as the computation of normalization
in order to compensate for technical differences and enable informative comparisons
between different genes. In addition, as discussed in Section 2.1.2.6, continuous gene
expression features are discretized by using the recursive minimal entropy partitioning
method [31] to fulfill the nominal features requirement of the entropy-based methods
[84].
4.1.2.3 Data Splitting
After the previous two steps, the processed clinical data along with gene expression
data are ready to use experimentally. The data is then split for the purpose of
calibration and validation. The half-and-half allocation is employed as discussed
in Section 2.2.4. Specifically, the lung cancer dataset consists of 86 primary lung
adenocarcinomas and 4,804 genes from the initial 7,129 genes, which were randomly
assigned to an equal number of patients, that is, 43 patients in the training set and
43 patients in the testing set. The renal cell dataset examined is comprised of 177
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patients and 4,438 genes after variation filter. This dataset was partitioned into a
training set of 89 patients and a test set of 88 patients.
4.1.3 Experimental Setup
All programs were developed using RStudio as the integrated development environment
for R programming language, with functions taken from DMwR, discretization,
survival, cluster, rpart, glm, coxph, caret, e1071, optim, constrOptim, cvTools,
and infotheo libraries for existing algorithms. Otherwise, data generation, data
preprocessing, variable selection in semiparametric cure models based on penalized
likelihood, and FCBF were implemented from scratch due to a lack of available
functions in the R library. All experiments were carried out on the compute nodes
“defiant” and “aalen” at Memorial University of Newfoundland.
4.1.4 Empirical Study and Comparison with Statistical
Methods
The objective of this section is to evaluate our proposed machine learning approach
for high-dimensional survival data and to compare its performance to state-of-the-art
statistical methods on real-world datasets.
4.1.4.1 Selecting Significant Clinical Parameters
Except for survival time, there are ten clinical parameters available from the lung
cancer dataset. As discussed in Chapter 3, the penalized logistic regression and the
penalized proportional hazard model are used to select significant clinical parameters.
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The full model, including all parameters, is also estimated as the reference. The
estimated coefficients in the full model and the final model selected by penalized
function are listed in Table 4.2.
Table 4.2: Selecting significant clinical parameters
Clinical Logistic Part Survival Part
Paramters Full Model Lasso Full Model Lasso
Age -0.117 0.148
Differentiation 0.172 -0.183 -0.129
Disease stage 1.178 1.320 1.531 1.681
Estrogen receptor 0.259 -0.196
K-ras mutation 0.338 0.321 0.465 0.481
Nodal status -0.408 -0.348 -0.250 -0.232
p53 nucl.accum. 0.291 0.217 0.371 0.154
Sex 0.065 -0.073
Smoking (pack years) -0.203 -0.328
Tumor size 0.565 0.547 0.407 0.421
As we can see from Table 4.2, the Lasso-penalized method suggests that clinical
parameters – disease stage, k-ras mutation, nodal status, p53 nucl.accum. and tumor
size – play a key role in predicting the patient’s probability of being cured. Regarding
the survival probability of the uncured patients, Lasso highlights one more clinical
parameter: differentiation. The optimal values of λ1 in logistic regression and λ2 in
survival regression that were selected by GCV are 0.381 and 0.012, respectively. Note
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that the intercept is always found in the logistic regression part, but considering that
our purpose is to select important clinical parameters instead of identifying the exact
model, this is not shown in Table 4.2. We therefore use these six important clinical
parameters to estimate censored survival time as discussed in Section 3.1.2.
4.1.4.2 Comparison of Feature Selections between Machine Learning and
the Statistical Perspective
Using FCBF, we generate a list of significant features. We compare FCBF with a
typical statistical approach in terms of the co-relations of the identified features to
the phenotypes of interest and the time they take to identify such a list of significant
genes.
The idea of Bair’s semi-supervised approach [3], covered in Chapter 2, is chosen
as a good fit for the comparison. First, FCBF and FSCS are used as representative
feature selection in machine learning and statistical feature selection, respectively,
to identify pairwise subsets of genes with the same target numbers ranging from 10
to 70. The identical classifier, that is, the nearest shrunken centroids procedure of
Tibshirani et al. [75], is then applied to these subsets of genes to classify patients
from the testing set into subgroups. We then use the log-rank test to obtain the
significance level at which the subgroups differ in survival time for each method. The
results are compared for both methods on the two aforementioned survival datasets.
Our motivation for using an identical classifier is that, since our main interest at this
stage is to compare the effectiveness and efficiency of the feature selection method
used by each approach, we would like to minimize the influences on the results from
the bias of the classifiers. The results are shown in Table 4.3 and 4.4, respectively.
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Table 4.3: Comparison of p-values from FSCS and FCBF applied to two datasets
when the nearest shrunken centroids is used as the identical classifier
Feature Selection p-values of different methods on two datasets
Method Lung Cancer Data Renal Cell Data
FSCS 0.0476 0.0374
FCBF 0.0107 0.0292
As shown in Table 4.3, both FCBF and FSCS identified lists of genes related to
patient survival and made significant statistical survival prediction. Genes such as
S100P , crk oncogene and VEGF, to name a few, known to be significantly survival-
associated in lung cancer that proven by clinical trials [78], were selected as correlated
with patient survival in our study. The best predictions obtained by FCBF are 0.0107
for the lung cancer data with 30 selected genes and 0.0292 for the renal cell data with
25 selected genes. FSCS yields its best p-value (0.0476) for the lung cancer data
when 55 genes are identified, and for renal cell data (p = 0.0374) when 50 genes are
identified. From the collection of p-values over these two datasets, we observe that
both FCBF and FSCS require a certain number of selected genes in order to arrive
at a significant survival prediction. One possible reason for this is if the number
of selected genes is limited, the information they contain is insufficient in return.
Also, FCBF method generally performs better than FSCS in cases where the number
of selected genes is limited and is able to make significant survival prediction with
fewer selected genes, which are consistent with the theoretical analysis demonstrating
FCBF’s ability to identify redundant features. The fact that selected significant genes
are not highly correlated with each other ensures that the information contained is
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maximized.
Table 4.4: Time taken (CPU units) by the FSCS and FCBF for a single trial on each
dataset
Feature Selection Dataset
Method Lung Cancer Data Renal Cell Data
FSCS 26.0 37.0
FCBF 3.0 8.0
Table 4.4 shows the execution times reported in CPU units on “aalen” for FSCS
and FCBF, and it is clear that FCBF runs significantly faster than FSCS. The FSCS
method consistently identifies significant genes by iteratively fitting a Cox model for
each gene. This can incur a relatively high cost in high-dimensional settings. On
the contrary, FCBF only calculates SU values to identify significant and redundant
genes, which are a linear time complexity and O(NMlogN) in terms of the number of
instances M and genes N, respectively. By identifying and removing the remaining
genes that are redundant peers to already identified genes in each iteration, the whole
process is also greatly accelerated. The results given in Table 4.4 verify FCBF’s
superior computational efficiency, which allows it to scale to larger datasets.
These experimental results suggest that feature selection in machine learning is
feasible for the analysis of high-dimensional survival data. It can effectively and
efficiently identify features truly associated with the phenotype of interest and can
enhance prediction with significant features.
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4.1.4.3 Comparison When Different Classifiers are Used
In order to compare feature selection in machine learning with feature selection from
a statistical perspective, we follow the idea of Bair’s semi-supervised approach to
cope with high-dimensional survival data and harness the identical classifier (i.e.,
the nearest shrunken centroids method), thus making feature selection methods the
only distinction between the two. Indeed, other than the nearest shrunken centroids
method, alternative learning algorithms from the machine learning community can
be paired with FCBF to improve the survival prediction power. For each dataset, we
run the four previously discussed statistical approaches (see Chapter 2) along with
our proposed procedure with the identical feature selection method FCBF and two
typical classifiers, NB and DT. The log-rank statistics comparing the survival time of
different subgroups obtained from different methods are recorded for comparison.
The Clustering-Cox method uses FSCS to compile a list of genes that correlate
with survival time and applies the nearest shrunken centroids to classify testing data
into the identified subgroups that fit with the training data. The list of top 55 genes
has the best overall association with survival, with a p-value held at 0.0476. The Risk
Index of the top 60 genes with the 60th percentile as a cutoff point identifies future
patients with a p-value of 0.0402. Our proposed method (FCBF in conjunction with
NB) yields a p-value of 0.0071 by selecting the 40 most significant genes. The FCBF
combined with DT has a p-value of 0.017 using the top 25 genes. In addition, Median-
Cut and Hierarchical Clustering are also employed, as representative supervised and
unsupervised approaches, respectively, to distinguish patients into subgroups. The
results of these methods applied to the lung cancer data and renal cell data are shown
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in Table 4.5.
Table 4.5: Comparison of different methods applied to two datasets. Median-Cut,
using median survival time to assign patients into cancer subtypes; Hierarchical
Clustering, using a clustering dendrogram to assign subtypes of patients based on
all genes; Clustering-Cox, using clustering based on the genes with the largest Cox
scores; Risk Index, using the cumulative effects of the significant genes selected with
the largest Cox scores; Na¨ıve Bayes, using FCBF in conjunction with Na¨ıve Bayes
classifier; and Decision Tree, using FCBF in conjunction with Decision Tree classifier.
Method
p-values of different methods on two datasets
Lung Cancer Data Renal Cell Data
Median-Cut 0.0287 0.0523
Hierarchical Clustering 0.078 0.0479
Clustering-Cox 0.0476 0.0374
Risk Index 0.0402 0.0489
Na¨ıve Bayes 0.0071 0.0106
Decision Tree 0.017 0.0247
Table 4.5 shows that our proposed approach for high-dimensional survival data is
predictive of survival and performs better than established methods. However, the
predictive results might differ in a single training-testing set due to random sampling
issues. Therefore, the leave one out cross-validation method is used to further validate
and generalize the results. Specifically, we first identify underlying subtypes and train
the classifier in each training set, which includes all patients except for the one that
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is held out from the full set as a test case. We then apply the trained classifier
to the single one test case and determine which subtype is present in the hold out
patient. Log-rank statistics comparing the survival times of different subgroups in
the test cases are computed to compare the effectiveness of different methods. The
efficiencies are indicated by the time needed to complete the whole leave one out trial
on each dataset with respect to a number of selected genes in each method. These
two results are shown in Table 4.6 and 4.7, respectively.
Table 4.6: Comparison of the leave one out approach of different methods applied to
two datasets. Median-Cut, using median survival time to assign patients into cancer
subtypes; Hierarchical Clustering, using clustering dendrogram to assign subtypes of
patients based on all genes; Clustering-Cox, using clustering based on the genes with
the largest Cox scores; Risk Index, using the cumulative effects of the significant genes
selected with the largest Cox scores; Na¨ıve Bayes, using FCBF in conjunction with
Na¨ıve Bayes classifier; and Decision Tree, using FCBF in conjunction with Decision
Tree classifier.
Method
Dataset
Lung Cancer Data Renal Cell Data
Median-Cut 0.0285 0.054
Hierarchical Clustering 0.069 0.0461
Clustering-Cox 0.0113 0.0098
Risk Index 0.0072 0.0121
Na¨ıve Bayes 0.0031 0.0057
Decision Tree 0.0085 0.0096
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The evaluation of Table 4.6 verifies that the proposed approach is effective for
high-dimensional survival data. It is capable of identifying subtypes of cancer and can
enhance the use of this knowledge to diagnose future patients. From Table 4.6, we can
see that our method made a much more significant statistical survival prediction than
other methods. In particular, Na¨ıve Bayes in conjunction with FCBF gives the best
results when 33 of the most significant genes are identified among lung cancer data
and 38 genes among renal cell data, with p-values of 0.0031 and 0.0057, respectively.
These results are significant predictors of survival. All methods in general undergo
a major improvement in their ability to predict patient survival expect for Median-
Cut; this is not surprising because the robustness of Median-Cut is mainly affected by
the degree of overlap between different groups rather than random sampling issues.
Therefore, although the leave one out approach provides more valuable information
with minimized random sampling issues, the performance of the Median-Cut method
is not necessarily enhanced. On the contrary, the performance improvement of other
methods agrees with the much more detailed sampling information provided by the
designed leave one out approach and the theory of how these methods work. Overall,
the enhanced leave one out approach depicts the robustness of our proposed method
and is a significant predictor of survival.
The results of Table 4.7 provide evidence regarding the efficiencies of different
methods. Median-Cut is extremely efficient because it only requires the calculation
of median time and can be trained at little expense. Therefore, although the leave one
out method is very expensive to compute, Median-Cut still runs in very little time
compared with other methods. The high cost of Hierarchical Clustering is primarily
attributed to calculating inter-group distance, as it does not involve feature selection,
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Table 4.7: Time taken (CPU units) by different methods for completing a leave one
out trial on each dataset with specific to a certain number of selected genes.
Method
Dataset
Lung Cancer Data Renal Cell Data
Median-Cut < 1.0 < 1.0
Hierarchical Clustering 82.0 297.0
Clustering-Cox 2241.0 7594.1
Risk Index 2417.0 8016.0
Na¨ıve Bayes 263.0 1476.0
Decision Tree 371.0 1730.0
and the classification step is also highly efficient. For the other four methods, different
classifiers do make a difference in the time needed to complete a leave one out trial on
each dataset for a certain number of selected genes, but it is the feature selection that
dictates the time variances. The running times of these four methods over the datasets
are in accordance with our previous time analysis shown in Table 4.4. However, since
each iteration of the leave one out method uses feature selection once, the running
time differences are additive. The larger the size of the sample and the greater
number of features contained in the sample (especially redundant ones), the greater
the difference between methods that employ FCBF and FSCS. Modern biomedical
technology has caused an explosion of data, which severs the small n large p problem.
Although predictive of survival, the Clustering-Cox and Risk Index methods are
time consuming. Therefore, improvements in the computational efficiencies of these
methods are warranted. Our proposed method merits with good scalability and is an
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efficient predictor of survival.
4.2 Experiments on Simulation Data
In this section, we carry out Monte Carlo simulations to evaluate our approach and
compare its performance to statistical methods.
4.2.1 Simulation Data Generation
In addition to the two real-world datasets, simulation data was also used to test
the effectiveness of the proposed method. Simulation imitates a real-world process
without the need to carry out a pilot test while it permitting a sufficient understanding
of the process and maximizing the benefits of limited resources. We designed a data
generation algorithm to specifically address survival time data. In particular, we used
a logistic distribution and Weibull distribution as examples to model covariates’ effect
on the patient’s probability of being cured and the survival probability of uncured
patients, respectively. The algorithm can be extended to generate other generic data
by employing the desired distributions and using any other proper survivor function
for which the inverse function is well defined. The data generation algorithm is
outlined as follows:
For predefined values of γ, β and p, as well as an identified covariate dimension,
d, we generate features X and Z for incidence and latency segments (without loss of
generality, we let Z = X ), survival time t, censoring indicator δ, and the indicator of
cured status, y, for each patient.
1. Randomly generate a realization Z or X with the desired dimensions, where
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each dimension is from a Bernoulli distribution with success parameter, p.
2. Randomly generate a realization censoring time tcensoring from a desired
distribution.
3. Compute the probability of being cured p (zi), where p (zi) = exp (γ ∗ z)/1 + exp (γ ∗ z).
Randomly generate a realization, y , from a Bernoulli distribution with success
parameter p (zi). If y = 1, then set δ = 0, tevent = +∞ and skip to step 7;
otherwise proceed in a stepwise fashion.
4. Compute λ = exp (β ∗ x).
5. Randomly generate a realization s0 from a desired distribution.
6. Compute tevent = (− log (s0))/(−λ)
7. Obtain the survival time t = min (tevent, tcensoring)
8. When y = 0, if tevent = min (tevent, tcensoring), then set δ = 1; otherwise δ =0.
Repetition n times of steps 1-8 results in a sample size of n. By selecting different
predefined values, we generate clinical data with expected settings to conduct Monte
Carlo simulations in the following section.
4.2.2 Results and Comparison with Statistical Methods
We first follow the data generation algorithm, proposed in the previous section, to
generate clinical data. The simulated clinical dataset consists of 10 covariates by
setting d =10 with γ = (0.5, 0, -0.6, 0.7, 0, 0, 0.3, 0, 0, 0.75, -0.75) and β = (-0.5,
0, 0.75, -0.15, 0, 0, -0.5, 0, 0.3, 0.3, -0.1), and 100 observations. Although we pay
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little attention to the intercept, it is part of the logistic regression and has the ability
to dominate the cure rate in simulation study. Therefore, the dimensions of both
parameters γ and β are 11 instead of 10, with the first dimension being the intercept.
Also, the number of nonzero coefficients, cure rate and censoring rate correspond to
the setting of lung cancer data. In terms of the setting of survival time, the censoring
time of each sample is generated as a uniform random number with a minimum value
of 2 and a maximum value of 16. The event time is generated with a value ranging
from 8 to 16 for samples 1-50, and 2 to 10 as event times for samples 51-100. Both
sets of event times are computed from s0, which follows the uniform distribution as
well.
Next, we generate gene expression data. By adjusting to the characteristics of
the gene expression data, different distributions are employed. The number of genes
is set as 5,000, which is close to the number of genes after the preprocessing step
in evaluating the lung cancer data. Rather than a Bernoulli distribution, all gene
expression values are generated as standard normal random numbers with a few
exceptions: a mean of 1.0 in genes 1-50 is generated for 30% randomly selected
samples, a mean of 2.0 in genes 51-200 is generated for 50% randomly selected samples,
and a mean of 0.5 in genes 200-400 is generated for 70% randomly selected samples.
We have now generated the clinical data and gene expression data for training.
We define samples 1-50 and 51-100 as belonging to “cancer subtype 1” and “cancer
subtype 2”, respectively. Finally, the program runs again with exactly the same
parameter settings to generate testing data. We evaluate the performance of the
penalized selection method by calculating the nonzero coefficients of the generated
clinical data. Performances of the other methods discussed are compared by applying
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them in the identification and determination of underlying subtypes in the training
and testing sets. Initial cluster errors are the number of misclassified samples when
the training data is originally divided into two subgroups, and prediction errors are
how many samples are mistakenly assigned subtypes in the testing set. Table 4.8 and
4.9 show the simulation results based on 100 replications.
Table 4.8: Simulation result of selecting significant parameters
Clinical
Paramters
Logistic Part Survival Part
True Value Estimated True Value Estimated
Coefficient Coefficient
Feature1 0 0 0 0
Feature2 -0.6 -0.63 0.75 0.7371
Feature3 0.7 0.71 -0.15 -0.1415
Feature4 0 0 0 0
Feature5 0 0 0 0
Feature6 0.3 0.3605 -0.5 -0.4712
Feature7 0 0 0 0
Feature8 0 0 0.3 0.3257
Feature9 -0.75 -0.7212 0.3 0.2975
Feature10 -0.75 -0.7487 -0.1 -0.147
In Table 4.8, we see that the Lasso-penalized method successfully selects the
nonzero coefficients of γ in the logistic regression part as well as correctly points out
the nonzero coefficients of β in the survival regression part. Table 4.9 shows that the
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Table 4.9: Comparison of different methods applied to simulation data. Median-
Cut, using median survival time to assign patients into cancer subtypes; Hierarchical
Clustering, using clustering dendrogram to assign subtypes of patients based on all
genes; Clustering-Cox, using clustering based on the genes with the largest Cox
scores; Risk Index, using the cumulative effects of the significant genes; Na¨ıve Bayes,
using FCBF in conjunction with Na¨ıve Bayes classifier; Decision Tree, using FCBF
in conjunction with Decision Tree classifier.
Method Initial Cluster Errors Prediction Errors
Median-Cut 36.6 53.8
Hierarchical Clustering 37.8 37.2
Clustering-Cox 20.3 16.4
Risk Index 15.5 12.5
Na¨ıve Bayes 7.2 4.1
Decision Tree 10.7 12.6
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fully supervised and fully unsupervised methods performed much more poorly than
other methods in this simulation study. The NB method gave the best results, with
both the fewest initial cluster errors and prediction errors. The DT method was the
second best in terms of initial cluster errors, and it performed slightly worse than the
Risk Index method with respect to prediction errors. Overall, both NB and DT made
good predictions. The simulation results are consistent with the results from the real
dataset and show the feasibility of the machine learning approach.
Along with the experiments on real datasets, these studies provide evidence
regarding the positive impact of the proposed machine learning approach to identify
survival-associated features and to predict patient survival from high-dimensional
survival data in an effective and efficient manner. More importantly, this work can
be considered as a preliminary study towards shaping a new research direction. More
detailed studies employing a broader range of various machine learning approaches
for the development of more powerful diagnostic tools for cancer are anticipated.
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Chapter 5
Conclusions and Future Work
The main objective of this research was to incorporate and promote the machine
learning approach to predict patient survival from high-dimensional survival data. To
accomplish this objective, the discretization of patient survival times via silhouettes
clustering validity was used as a strategy to overcome the obstacle of hidden class
information in high-dimensional survival data. Class discovery allowed feature
selection in machine learning to identify features truly associated with survival.
Classifiers were then applied to a subset of selected features to predict subtypes
for future groups of patients; therefore, the prediction was based on survival-
associated information contained in the high-dimensional survival data. The leave one
out method validated and enhanced the identification and predication performance
(Chapter 3). Finally, an empirical study was conducted on real datasets, as well as
simulation datasets, to test the ability of the proposed method to predict patient
survival from high-dimensional survival data (Chapter 4). The primary contributions
of this research as well as the potential future directions are outlined in the reminder
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of this chapter.
5.1 Research Contributions
Although many studies have focused on developing statistical methods to select
survival-associated features and to predict cancer subtypes from the genetic profile
of a tumor, research in this area from a machine learning perspective has been
underexplored [4, 22, 11]. Therefore, the main contribution of this research was
the design and development of a novel machine learning approach that utilizes both
gene expression data and clinical data to discover and predict cancer subtypes. Our
procedure employed the delicate discretization method on event times to enable the
use of feature selection in machine learning. A strategy was found that makes it
possible to choose from the rich repository of feature selection and classification
methods proposed by computer scientists in the machine learning community to select
survival-associated features and to predict cancer subtypes from high-dimensional
survival data.
A fundamental research question in applying such a procedure was, how can
machine learning approaches be applied to predict patient survival from high-dimensional
survival data? Although feature selection in machine learning can identify relevant
features as well as redundancy among them in an efficient manner, the application
of machine learning methods in the analysis of high-dimensional survival data is
underexplored. The main obstacle encountered in using these methods for high-
dimensional survival data is the lack of explicit class labels in the training set. Unlike
statistical approaches that use the Cox score to quantify how well each feature predicts
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survival, which is independent of the availability of a class label, feature selection in
machine learning is dependent on class label. Therefore, we chose to apply the delicate
discretization method on the survival time of patients to find the hidden class label.
In contrast to classical statistical methods that keep censoring individuals in the
risk set along with other individuals who have not yet experienced the event, we use
the k-nearest neighbor to address censoring, which is based on clinical parameters
that are truly associated with survival time. In order to validate the chosen design
and to enhance identification and prediction performance, a leave one out method was
employed. This research opens a range of possibilities for future work on selecting
survival-associated genes and identifying cancer subtypes from a different research
direction.
After designing and developing this approach, a second research question emerged:
What is the feasibility of using the machine learning approach for high-dimensional
survival data? To answer this question, an empirical study was conducted to compare
the performance of our proposed method on high-dimensional survival data with
related methods in the literature using publicly available datasets and simulated
datasets. The results of the real datasets and the simulation datasets conclusively
match, which suggests that our proposed method is an effective and efficient predictor
of survival. Our proposed approach is capable of selecting features truly associated
with survival and enhancing prediction with significant features. The subgroups
determined in the test cases differed significantly in their overall survival, with p-
values of 0.0031 and 0.0057 for lung cancer data and renal cell data, respectively.
Our method proved to be superior to the others with both the fewest initial cluster
errors and prediction errors in the simulation study. With respect to efficiency, our
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method demonstrated promising capability in dealing with high-dimensional survival
data. It is significantly faster in selecting a certain number of significant genes,
especially when the leave one out method was used; its computational efficiency had
a fuller exposure that is 10 and 5 times faster for lung cancer data and renal cell data,
respectively.
As discussed in Chapter 4, these findings indicate that the machine learning
approach is feasible for the analysis of high-dimensional survival data. To the best
of our knowledge, no other work has explored this approach in a systematic way. As
such, our work can serve as a complementary paradigm for classical survival prediction
in high-dimensional space. More research along this direction is warranted. Some
potential topics for future work are discussed in the next section.
5.2 Future Work
The results of the empirical study reveal the ability of the proposed strategy to select
survival-associated features and to predict patient survival from high-dimensional
survival data. This indicates that there is an opportunity to discover the hidden class
label based on other clinical information, such as the stage of the tumor, or whether
it has metastasized. For example, information about the risk of metastasis for a given
patient is essential for the design of more targeted treatment strategies [11]. If the
risk of metastasis is high, the cancer must be treated aggressively, even if serious toxic
effects are likely; on the other hand, a milder regimen can be administered to patients
with a low risk of metastasis. Therefore, the clinical information of metastasis can
be regarded as the phenotype of interest and used to find the hidden class label.
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Similarly, genes can be selected based on their association with the risk of metastasis,
and this knowledge can be used to identify subgroups by their differences in this
respect. Tusher et al. described methods for selecting a phenotype of interest from
a variety of possible clinical variables [78]. An appealing research direction is to find
the hidden class label based on multiple phenotypes of interest and the interactions
between them [71]. Furthermore, in this research, we adopt the methods largely
based on their performance in classical machine learning applications, which are not
necessarily the best in the context of survival prediction. What criterion we should
use in selecting an approach for survival prediction from the very rich repository of
the machine learning methods is an interesting topic to explore [7].
There is value in choosing features with the help of purported biological knowledge,
despite the fact that this approach is irrespective of this knowledge. For instance,
genes involved in specific biological pathways or those that have an established
involvement in the disease process under study can be selected in advance to aid in
the selection of phenotype-associated genes [78, 71], which may lead to more accurate
subtype predictions. In order to expand the analysis of high-dimensional survival
data, there must be a significant attempt to include interdisciplinary collaborations
[55]. Moreover, even with ways of selecting phenotype-associated features, how to
identify environmental factors that increase the risk of cancer is one of the greatest
challenges of the research agenda [53].
In this research, the proposed method was applied and evaluated on two real-
world datasets that were obtained from completed studies. In order to analyze high-
dimensional survival data and assess the performance of our proposed method on
datasets obtained from ongoing studies in the future (data become available only
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at certain points in time, as in clinical decision making), a sequential classification
scheme could be applied [77]. This way, patients are classified only upon sufficient
evidence and the repeated use of additional data.
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